Latest & greatest articles for breast cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on breast cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on breast cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for breast cancer

161. Gene Expression Tests for Women with Early Stage Breast Cancer: A Review of Clinical Utility and Cost-Effectiveness

Gene Expression Tests for Women with Early Stage Breast Cancer: A Review of Clinical Utility and Cost-Effectiveness Gene Expression Tests for Women with Early Stage Breast Cancer: A Review of Clinical Utility and Cost-Effectiveness | CADTH.ca Find the information you need Gene Expression Tests for Women with Early Stage Breast Cancer: A Review of Clinical Utility and Cost-Effectiveness Gene Expression Tests for Women with Early Stage Breast Cancer: A Review of Clinical Utility and Cost (...) -Effectiveness Published on: October 16, 2017 Project Number: RC0934-000 Product Line: Research Type: Other Diagnostics Report Type: Summary with Critical Appraisal Result type: Report Question What is the comparative clinical utility of gene expression tests to either predict adjunct chemotherapy or evaluate cancer recurrence risk in women with early stage breast cancer? What is the comparative cost-effectiveness of gene expression tests to either predict adjunct chemotherapy or evaluate cancer recurrence

Canadian Agency for Drugs and Technologies in Health - Rapid Review2017

162. Liquid biopsy for HER2-positive breast cancer brain metastasis: the role of the cerebrospinal fluid

Liquid biopsy for HER2-positive breast cancer brain metastasis: the role of the cerebrospinal fluid 29067217 2018 11 13 2059-7029 2 4 2017 ESMO open ESMO Open Liquid biopsy for HER2-positive breast cancer brain metastasis: the role of the cerebrospinal fluid. e000270 10.1136/esmoopen-2017-000270 De Mattos-Arruda Leticia L Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. eng Editorial 2017 10 09 England ESMO Open 101690685 2059-7029 Nat Med. 2015 Jul;21(7):751-9 26099045 Clin Chem (...) ):464-74 26776681 PLoS Med. 2016 Dec 27;13(12 ):e1002201 28027327 Cancer Discov. 2015 Nov;5(11):1164-1177 26410082 Lancet Oncol. 2013 Jan;14(1):64-71 23122784 J Natl Cancer Inst. 2015 Nov 07;108(2): 26547932 Cancer Cell. 2017 Aug 14;32(2):169-184.e7 28810143 brain metastasis cell-free DNA cerebro-spinal fluid liquid biopsy metastatic breast cancer Competing interests: None declared. 2017 09 01 2017 09 05 2017 10 26 6 0 2017 10 27 6 0 2017 10 27 6 1 epublish 29067217 10.1136/esmoopen-2017-000270

ESMO open2017 Full Text: Link to full Text with Trip Pro

163. Genotyping tumour DNA in cerebrospinal fluid and plasma of a HER2-positive breast cancer patient with brain metastases

Genotyping tumour DNA in cerebrospinal fluid and plasma of a HER2-positive breast cancer patient with brain metastases 29067216 2018 11 13 2059-7029 2 4 2017 ESMO open ESMO Open Genotyping tumour DNA in cerebrospinal fluid and plasma of a HER2-positive breast cancer patient with brain metastases. e000253 10.1136/esmoopen-2017-000253 Central nervous system (CNS) involvement contributes to significant morbidity and mortality in patients with human epidermal growth factor receptor 2 (HER2 (...) )-positive metastatic breast cancer (mBC) and represents a major challenge for clinicians. Liquid biopsy of cerebrospinal fluid (CSF)-derived circulating tumour DNA (ctDNA) harbours clinically relevant genomic alterations in patients with CNS metastases and could be effective in tracking tumour evolution. In a HER2-positive mBC patient with brain metastases, we applied droplet digital PCR (ddPCR) and next-generation whole exome sequencing (WES) analysis to measure ctDNA dynamic changes in CSF and plasma

ESMO open2017 Full Text: Link to full Text with Trip Pro

164. Clinicopathological features and survival of early stage breast cancer in northwest China: A population‐based retrospective study of 1287 patients

Clinicopathological features and survival of early stage breast cancer in northwest China: A population‐based retrospective study of 1287 patients 28976077 2018 11 02 2018 11 13 1759-7714 9 1 2018 01 Thoracic cancer Thorac Cancer Clinicopathological features and survival of early stage breast cancer in northwest China: A population-based retrospective study of 1287 patients. 10-18 10.1111/1759-7714.12503 Breast cancer (BC) displays different clinicopathological features and outcomes based (...) Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. Yi Min M Department of Translational Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. Yang Jin J Department of Medical Oncology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. eng Journal Article 2017 10 04 Singapore Thorac Cancer 101531441 1759-7706 IM Int J Cancer. 2015 Mar 1;136(5):E359-86 25220842 Cancer. 2001 Apr 15;91(8 Suppl):1679-87 11309768 Breast

Thoracic cancer2017 Full Text: Link to full Text with Trip Pro

165. Breast cancer risk factors in relation to estrogen receptor, progesterone receptor, insulin-like growth factor-1 receptor, and Ki67 expression in normal breast tissue

Breast cancer risk factors in relation to estrogen receptor, progesterone receptor, insulin-like growth factor-1 receptor, and Ki67 expression in normal breast tissue 28979927 2018 11 13 2374-4677 3 2017 NPJ breast cancer NPJ Breast Cancer Breast cancer risk factors in relation to estrogen receptor, progesterone receptor, insulin-like growth factor-1 receptor, and Ki67 expression in normal breast tissue. 39 10.1038/s41523-017-0041-7 Studies have suggested that hormone receptor and Ki67 (...) expression in normal breast tissue are associated with subsequent breast cancer risk. We examined the associations of breast cancer risk factors with estrogen receptor (ER), progesterone receptor (PR), insulin-like growth factor-1 receptor (IGF-1R), and Ki67 expression in normal breast tissue. This analysis included 388 women with benign breast disease (ages 17-67 years) in the Nurses' Health Studies. Immunohistochemical staining was performed on tissue microarrays constructed from benign biopsies

NPJ breast cancer2017 Full Text: Link to full Text with Trip Pro

166. Digital Breast Tomosynthesis with Hologic 3D mammograhy Selenia Dimensions System for use in breast cancer screening

Digital Breast Tomosynthesis with Hologic 3D mammograhy Selenia Dimensions System for use in breast cancer screening Digital Breast Tomosynthesis with Hologic 3D mammography Selenia Dimensions System for use in breast cancer screening - NIPH Selected items added to basket Close Vis søkefelt How can we help you today? Search for: Søk Menu • • Digital Breast Tomosynthesis with Hologic 3D mammography Selenia Dimensions System for use in breast cancer screening Søk i Folkehelsa.no Search for: Søk (...) Infectious diseases & Vaccines Close Mental & Physical health Close Environment & Lifestyle Close Health in Norway Close Quality & Knowledge Close Research & Access to data Close Skip to content Background In Norway, breast cancer screening is offered through a publicly funded program to women in the age group 50-69 on a biennial basis. Breast cancer incidence is relatively higher among women in this age group than it is among younger women. The purpose of the screening program is to reduce breast cancer

The Norwegian Knowledge Centre for the Health Services2017

168. Gene Expression Profiling in Breast Cancer and Its Effect on Therapy Selection in Early-Stage Breast Cancer

Gene Expression Profiling in Breast Cancer and Its Effect on Therapy Selection in Early-Stage Breast Cancer 29082373 2018 11 13 13 4 2017 Oct European journal of breast health Eur J Breast Health Gene Expression Profiling in Breast Cancer and Its Effect on Therapy Selection in Early-Stage Breast Cancer. 168-174 10.5152/ejbh.2017.3636 Breast cancer is a heterogeneous disease. The purpose of adjuvant therapy for early-stage breast cancer is to provide maximum benefit with minimum side effects (...) in recent years, is beneficial in therapy selection for luminal breast cancer cases. A differentiation can be made among patients for whom only endocrine treatment would be adequate and those who should also receive chemotherapy in addition to endocrine treatment. Several new gene expression analysis studies targeted at gaining the ability to determine drug selection in chemotherapy, endocrine treatment and neo-adjuvant therapy are also currently ongoing. The staging system for new breast cancer

European journal of breast health2017 Full Text: Link to full Text with Trip Pro

169. Roles of Biopsychosocial Factors in the Development of Breast Cancer

Roles of Biopsychosocial Factors in the Development of Breast Cancer 29082379 2018 11 13 13 4 2017 Oct European journal of breast health Eur J Breast Health Roles of Biopsychosocial Factors in the Development of Breast Cancer. 206-212 10.5152/ejbh.2017.3519 The aim of this study was to determine the roles of biopsychosocial risk factors in the development of breast cancer. This hospital-based case-control study included 491 women with breast cancer (study group) and 512 women who did not have (...) cancer or other serious diseases (control group). Biological, psychological, and social risk factors were compared between the two groups. Data were collected using the semi-structured interview, the Stress Assessment Form, and the Coping Strategy Indicator to assess these factors. When the significantly different biopsychosocial variables between the study and the control groups were evaluated together, independent breast cancer risk factors were found as follows: a stressor experienced in the last

European journal of breast health2017 Full Text: Link to full Text with Trip Pro

170. Bilateral Breast Cancer with Neurofibromatosis Type 1 Patient: Case Report

Bilateral Breast Cancer with Neurofibromatosis Type 1 Patient: Case Report 29082380 2018 11 13 13 4 2017 Oct European journal of breast health Eur J Breast Health Bilateral Breast Cancer with Neurofibromatosis Type 1 Patient: Case Report. 213-215 10.5152/ejbh.2017.3105 Neurofibromatosis type 1 (NF1) is autosomal dominant and it is the most common hereditary disease. This case report is about a woman and her daughter. Both of them are NF1 and mother also has metachronous bilateral breast (...) profiles were observed and the expression of DDB2, MGMT, MLH1, POLB UNG, XPA genes were high in both mother and daughter. In sequencing analysis, we obtained a mutation in c.1246 C>T. This mutation is reported to be common in NF1 cases with breast carcinoma. Our results indicate that the daughter with NF1 is probably prone to have malignancy in her future life. She should be carefully followed up for early diagnosis of a probable malignancy. Dursun Duygu D Institute of Oncology, Dokuz Eylül University

European journal of breast health2017 Full Text: Link to full Text with Trip Pro

171. The Spectrum Theory in Breast Cancer Is Controversial

The Spectrum Theory in Breast Cancer Is Controversial 29082382 2018 11 13 13 4 2017 Oct European journal of breast health Eur J Breast Health The Spectrum Theory in Breast Cancer Is Controversial. 219-220 10.5152/ejbh.2017.3721 Kayar Ragıp R Free surgeon, General Surgery, İzmir, Turkey. eng Journal Article 2017 10 01 Turkey Eur J Breast Health 101709357 J Plast Reconstr Aesthet Surg. 2007;60(5):495-502 17399658 Br J Surg. 2015 May;102(6):599-610 25787293 Clin Plast Surg. 2015 Jul;42(3):339-44

European journal of breast health2017 Full Text: Link to full Text with Trip Pro

172. Differences in Perception of Breast Cancer Among Muslim and Christian Women in Ghana

Differences in Perception of Breast Cancer Among Muslim and Christian Women in Ghana 30241158 2018 11 15 2378-9506 4 2018 Sep Journal of global oncology J Glob Oncol Differences in Perception of Breast Cancer Among Muslim and Christian Women in Ghana. 1-9 10.1200/JGO.2017.009910 The burden of breast cancer continues to increase in low- and middle-income countries (LMICs), where women present with more advanced disease and have worse outcomes compared with women from high-income countries (...) . In the absence of breast cancer screening in LMICs, patients must rely on self-detection for early breast cancer detection, followed by a prompt clinical diagnostic work-up. Little is known about the influence of religious beliefs on women's perceptions and practices of breast health. A cross-sectional survey was administered to female members of Islamic and Christian organizations in Ghana. Participants were asked about their personal experience with breast concerns, knowledge of breast cancer, performance

Journal of global oncology2017 Full Text: Link to full Text with Trip Pro

173. A Mobile Breast Cancer Survivorship Care App: Pilot Study

A Mobile Breast Cancer Survivorship Care App: Pilot Study 28951383 2018 11 13 2369-1999 3 2 2017 Sep 26 JMIR cancer JMIR Cancer A Mobile Breast Cancer Survivorship Care App: Pilot Study. e14 10.2196/cancer.8192 Cancer survivors living in rural areas experience unique challenges due to additional burdens, such as travel and limited access to specialists. Rural survivors of breast cancer have reported poorer outcomes, poorer mental health and physical functioning, and lower-than-average quality (...) of life compared to urban survivors. To explore the feasibility and acceptability of developing a mobile health survivorship care app to facilitate care coordination; support medical, psychosocial, and practical needs; and improve survivors' long-term health outcomes. An interactive prototype app, SmartSurvivor, was developed that included recommended survivorship care plan components. The prototype's feasibility and acceptability were tested by a sample of breast cancer survivors (n=6), primary care providers

JMIR cancer2017 Full Text: Link to full Text with Trip Pro

174. Randomized phase III trial evaluating the role of weight loss in adjuvant treatment of overweight and obese women with early breast cancer (Alliance A011401): study design

Randomized phase III trial evaluating the role of weight loss in adjuvant treatment of overweight and obese women with early breast cancer (Alliance A011401): study design 28948213 2018 11 13 2374-4677 3 2017 NPJ breast cancer NPJ Breast Cancer Randomized phase III trial evaluating the role of weight loss in adjuvant treatment of overweight and obese women with early breast cancer (Alliance A011401): study design. 37 10.1038/s41523-017-0040-8 Excess body weight is a poor prognostic factor (...) in women with early breast cancer, but the effect of weight loss on the risk of breast cancer recurrence and mortality in women who are overweight or obese at the time of breast cancer diagnosis has not been evaluated. The Alliance for Clinical Trials in Oncology Breast Cancer Weight Loss trial, also known as A011401, is testing the impact of a telephone-based weight loss program on invasive disease-free survival in 3136 women with a body mass index ≥27 kg/m 2 who have recently been diagnosed

NPJ breast cancer2017 Full Text: Link to full Text with Trip Pro

175. Defects in mismatch repair: the Achilles heel of estrogen receptor positive breast cancer with intrinsic endocrine therapy resistance?

Defects in mismatch repair: the Achilles heel of estrogen receptor positive breast cancer with intrinsic endocrine therapy resistance? 28966940 2018 11 13 2331-4737 4 7-8 2017 Jul Oncoscience Oncoscience Defects in mismatch repair: the Achilles heel of estrogen receptor positive breast cancer with intrinsic endocrine therapy resistance? 77-78 10.18632/oncoscience.363 Haricharan Svasti S Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX 77030, USA. Ellis Matthew J MJ (...) Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX 77030, USA. eng Editorial 2017 09 21 United States Oncoscience 101636666 2331-4737 Nature. 2013 Aug 22;500(7463):415-21 23945592 Front Oncol. 2014 May 14;4:106 24860786 Clin Cancer Res. 2017 Aug 1;23 (15):4055-4065 28270497 Nature. 2017 Aug 24;548(7668):471-475 28813415 CONFLICTS OF INTEREST The authors declare no conflicts of interest. 2017 09 20 2017 09 20 2017 10 3 6 0 2017 10 3 6 0 2017 10 3 6 1 epublish 28966940 10.18632

Oncoscience2017 Full Text: Link to full Text with Trip Pro

176. A Lifestyle Intervention via Email in Minority Breast Cancer Survivors: Randomized Parallel-Group Feasibility Study

A Lifestyle Intervention via Email in Minority Breast Cancer Survivors: Randomized Parallel-Group Feasibility Study 28935620 2018 11 13 2369-1999 3 2 2017 Sep 21 JMIR cancer JMIR Cancer A Lifestyle Intervention via Email in Minority Breast Cancer Survivors: Randomized Parallel-Group Feasibility Study. e13 10.2196/cancer.7495 Our data have indicated that minority breast cancer survivors are receptive to participating in lifestyle interventions delivered via email or the Web, yet few Web-based (...) studies exist in this population. The aim of this study was to examine the feasibility and preliminary results of an email-delivered diet and activity intervention program, "A Lifestyle Intervention Via Email (ALIVE)," delivered to a sample of racial and ethnic minority breast cancer survivors. Survivors (mean age: 52 years, 83% [59/71] African American) were recruited and randomized to receive either the ALIVE program's 3-month physical activity track or its 3-month dietary track. The fully automated

JMIR cancer2017 Full Text: Link to full Text with Trip Pro

177. Divergent JNK Phosphorylation of HDAC3 in Triple Negative Breast Cancer Cells Determines HDAC Inhibitor Binding and Selectivity

Divergent JNK Phosphorylation of HDAC3 in Triple Negative Breast Cancer Cells Determines HDAC Inhibitor Binding and Selectivity 28943357 2017 12 26 2018 11 16 2451-9448 24 11 2017 Nov 16 Cell chemical biology Cell Chem Biol Divergent JNK Phosphorylation of HDAC3 in Triple-Negative Breast Cancer Cells Determines HDAC Inhibitor Binding and Selectivity. 1356-1367.e8 S2451-9456(17)30313-6 10.1016/j.chembiol.2017.08.015 Histone deacetylase (HDAC) catalytic activity is regulated by formation of co (...) -regulator complexes and post-translational modification. Whether these mechanisms are transformed in cancer and how this affects the binding and selectivity of HDAC inhibitors (HDACis) is unclear. In this study, we developed a method that identified a 3- to 16-fold increase in HDACi selectivity for HDAC3 in triple-negative breast cancer (TNBC) cells in comparison with luminal subtypes that was not predicted by current practice measurements with recombinant proteins. We found this increase was caused

Cell chemical biology2017 Full Text: Link to full Text with Trip Pro

178. Ribociclib for Metastatic Breast Cancer – Details

Ribociclib for Metastatic Breast Cancer – Details Ribociclib for Metastatic Breast Cancer – Details | CADTH.ca Find the information you need Ribociclib for Metastatic Breast Cancer – Details Ribociclib for Metastatic Breast Cancer – Details Project Number pCODR 10112 Brand Name TBD Generic Name Ribociclib Tumour Type Breast Indication Advanced or Metastatic Breast Cancer Funding Request For the treatment of postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor (...) receptor 2 (HER2)-negative advanced or metastatic breast cancer, as an initial endocrine-based therapy Review Status Pending Pre Noc Submission Yes NOC Date Manufacturer Novartis Pharmaceuticals Canada Inc. Submitter Novartis Pharmaceuticals Canada Inc. Submission Date (Target Date) October 17, 2017 Submission Type New Drug Prioritization Requested Stakeholder Input Deadline (target date based on target submission date) ‡ October 31, 2017 Check-point meeting (target date) pERC Meeting (target date

CADTH - Pan Canadian Oncology Drug Review2017

179. Video intervention increases participation of black breast cancer patients in therapeutic trials

Video intervention increases participation of black breast cancer patients in therapeutic trials 28944289 2018 11 13 2374-4677 3 2017 NPJ breast cancer NPJ Breast Cancer Video intervention increases participation of black breast cancer patients in therapeutic trials. 36 10.1038/s41523-017-0039-1 There is a striking racial and ethnic disparity in incidence and mortality of cancer yet minorities remain markedly underrepresented in clinical trials. This pilot study set out to determine the impact (...) of a 15-min culturally tailored educational video on three outcomes relating to clinical trials: likely participation, attitudes (assessed based on six barriers), and actual enrollment. Breast cancer patients with Stage I-III, if diagnosed within previous 6 months, or metastatic disease who self-identified as black or African American were invited to participate. The primary outcome measure was the decision to participate in a therapeutic clinical trial after the intervention. Patients' intention

NPJ breast cancer2017 Full Text: Link to full Text with Trip Pro

180. How many diseases is triple negative breast cancer: the protagonism of the immune microenvironment

How many diseases is triple negative breast cancer: the protagonism of the immune microenvironment 29018573 2018 11 13 2059-7029 2 4 2017 ESMO open ESMO Open How many diseases is triple negative breast cancer: the protagonism of the immune microenvironment. e000208 10.1136/esmoopen-2017-000208 Triple negative breast cancer (TNBC) is a type of breast cancer (BC) that does not express the oestrogen and the progesterone receptors and the human epidermal growth factor receptor type 2 (HER2). Since (...) there are no positive markers to reliably classify TNBC, these tumours are not yet treated with targeted therapies. Perhaps for this reason they are the most aggressive form of breast carcinomas. However, the clinical observation that these patients do not carry a uniformly dismal prognosis, coupled with data coming from pathology and epidemiology, suggests that this negative definition is not capturing a single clinical entity, but several. We critically evaluate this evidence in this paper, reviewing clinical

ESMO open2017 Full Text: Link to full Text with Trip Pro